Recent advances in use of fresh frozen plasma, cryoprecipitate, immunoglobulins, and clotting factors for transfusion support in patients with hematologic disease

16Citations
Citations of this article
131Readers
Mendeley users who have this article in their library.

Your institution provides access to this article.

Abstract

Hematologic diseases include a broad range of acquired and congenital disorders, many of which affect plasma proteins that control hemostasis and immune responses. Therapeutic interventions for these disorders include transfusion of plasma, cryoprecipitate, immunoglobulins, or convalescent plasma-containing therapeutic antibodies from patients recovering from infectious diseases, as well as concentrated pro- or anticoagulant factors. This review will focus on recent advances in the uses of plasma and its derivatives for patients with acquired and congenital hematologic disorders.

Cite

CITATION STYLE

APA

Nair, P. M., Rendo, M. J., Reddoch-Cardenas, K. M., Burris, J. K., Meledeo, M. A., & Cap, A. P. (2020, April 1). Recent advances in use of fresh frozen plasma, cryoprecipitate, immunoglobulins, and clotting factors for transfusion support in patients with hematologic disease. Seminars in Hematology. W.B. Saunders. https://doi.org/10.1053/j.seminhematol.2020.07.006

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free